Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 2006

View Archived Issues

CE Mark for Tag-It Cystic Fibrosis Kit

ActivBiotics and Metaphore Pharmaceuticals complete merger

Pharmacopeia earns milestone payment in Organon collaboration

New multidose study of Riquent planned in lupus patients

Studies show BioThrax plus antibiotics protect animals post anthrax exposure

Japanese licensing deal for Fentanyl Taifun

Corautus Genetics to support study of VEGF-2 in critical limb ischemia

Salix offers development update

Duloxetine 60 mg once daily found safe and effective in fibromyalgia patients

GE-81112 factor B: A novel prokaryotic-specific protein synthesis inhibitor

Human Genome Sciences receives milestone for GSK-716155 IND filing

Mylan and Forest sign nebivolol agreement

Ablynx and Centocor sign Nanobodies agreement

Phase IIa study of ATL-1102 restarts

Safety data review in phase III study of Intercell's Japanese encephalitis vaccine

Russian approvals for HER-2 Protein AutoVac vaccine phase II trial

Placebo group assumptions correct in phase IIb study of VLTS-934 in intermittent claudication

Novel orally active CB1 receptor inverse agonist decreases food intake in rodents

Novel orally active and in vivo effective p38alpha MAPK inhibitors from Novartis

FDA issues guidance to improve efficiency of earliest stages of clinical testing

Recent patents report novel therapeutic agents for anxiety, depression, etc.

Novel possible treatment options for cancer disclosed in patent literature

First launch for Dong-A erectile dysfunction therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...